Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
DC10796 | Prexasertib (LY2606368) Featured |
LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase.
More description
|
![]() |
DC8852 | SW-044248 Featured |
SW-044248 is a Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines.
More description
|
![]() |
DC10632 | Sitravatinib (MGCD516) Featured |
Sitravatinib (MGCD516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.
More description
|
![]() |
DC11450 | Selpercatinib(LOXO-292) Featured |
Selpercatinib is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively. Antineoplastic activity.
More description
|
![]() |
DC10479 | RX518(CK-101:EGFR-IN-3) Featured |
RX518(CK-101) is an orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations.
More description
|
![]() |
DC1091 | PF-299804 (Dacomitinib,PF-00299804) Featured |
PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively.
More description
|
![]() |
DC2047 | Crizotinib (PF-2341066) Featured |
PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley.
More description
|
![]() |
DC7924 | PF06463922(Lorlatinib) Featured |
PF06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.
More description
|
![]() |
DC7225 | Pelitinib (EKB-569; WAY-EKB 569) Featured |
Pelitinib (EKB-569; WAY-EKB 569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM.
More description
|
![]() |
DC7084 | Nintedanib (BIBF 1120) Featured |
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM.
More description
|
![]() |
DC8608 | BIBF 1120 esylate Featured |
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM.
More description
|
![]() |
DC7200 | Motesanib Diphosphate (AMG-706) Featured |
Motesanib (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret.
More description
|
![]() |
DC10282 | ML385 Featured |
ML385 is a novel and specific NRF2 inhibitor.
More description
|
|
DC1070 | MK-1775(AZD-1775,Adavosertib) Featured |
MK-1775 is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM.
More description
|
![]() |
DC10219 | LY3023414 Featured |
LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK.
More description
|
![]() |
DC7993 | Prexasertib (LY2606368) 2HCl Featured |
LY2606368 2Hcl is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase.
More description
|
![]() |
DC10828 | LXH254 Featured |
LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor.
More description
|
![]() |
DC11900 | Lazertinib Featured |
Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations
More description
|
![]() |
DC7167 | Capmatinib(INCB28060) Featured |
INCB28060 is a novel orally active inhibitor (IC50=0.13 nM) of c-MET kinase.
More description
|
![]() |
DC8491 | GSK2879552 Featured |
GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
More description
|
![]() |
DC11543 | Glumetinib Featured |
Glumetinib (SCC 244) is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM.
More description
|
![]() |
DC2103 | Gefitinib (ZD1839) Featured |
Gefitinib (Iressa, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.
More description
|
![]() |
DC7342 | Foretinib(XL880) Featured |
Foretinib (GSK1363089; XL880; EXEL-2880; GSK089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR.
More description
|
![]() |
DC3139 | Erlotinib hydrochloride Featured |
Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM.
More description
|
![]() |
DC8300 | Entrectinib (RXDX-101) Featured |
Entrectinib (RXDX-101), a potent and selective small molecule inhibitor of TrkA/B/C, ROS1, and ALK kinases, has demonstrated early clinical activity when orally administered intermittently under fasting conditions.
More description
|
![]() |
DC7695 | Defactinib (VS-6063, PF-04554878) Featured |
Defactinib is a potent, selective, and orally active FAK inhibitor with demonstrated tolerability and preliminary clinical activity working as a single agent as well as in combination with paclitaxel.
More description
|
![]() |
DC10527 | Ciforadenant (CPI-444) Featured |
CPI-444 is an orally administered antagonist of the adenosine A2A receptor. It is designed to block the action of adenosine that is produced by tumors.
More description
|
![]() |
DC7106 | Rociletinib (CO-1686) Featured |
CO-1686 is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M(IC50=21 nM).
More description
|
![]() |
DC7383 | CH5424802(Alectinib) Featured |
CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.
More description
|
![]() |
DC3138 | Canertinib dihydrochloride Featured |
Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities.
More description
|
![]() |